ArticleBMC ophthalmology2026
Predictors of treatment response to subthreshold micropulse laser and oral spironolactone therapy for central serous chorioretinopathy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Steroid-Induced Central Serous Chorioretinopathy in Uveitis: Diagnostic Challenges and Multimodal Imaging with a Primary Inflammatory Choriocapillaropathy Illustrative Case.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo identify the specific predictors of treatment response to subthreshold micropulse laser (SML) and oral spironolactone therapy in patients with central serous chorioretinopathy (CSC).
methodsPatients diagnosed with CSC and treated with SML or spironolactone were included in this cohort study. Baseline characteristics, systemic factors, and various imaging characteristics were included as potential predictors of treatment response. Univariate and multivariate analysis was performed to identify predictive factors for the disease.
resultsA total of 103 eyes from 97 patients were included and divided into SML group (52 eyes) and spironolactone group (51 eyes). SRF resolution and OCT parameters, including CRT (p = 0.018) and SRF height (p < 0.001), decreased significantly in both groups, but SFCT decreased only in the spironolactone group. Regression analysis revealed that baseline SRF area was correlated with disease resolution in both SML (p = 0.005) and spironolactone (p = 0.016) groups, whereas changes in CRT and SFCT were correlated with a history of hyperuricemia (p = 0.047) and drinking (p = 0.035) only in the spironolactone group.
conclusionBoth SML and oral spironolactone are alternative therapies with similar efficacy. The SRF area at baseline can be a predictor of disease resolution. A history of hyperuricemia and drinking correlates with worse efficacy with spironolactone treatment.
trial registrationThe study was registered on Chinese Clinical Trial Registry (identifier: ChiCTR2100044356) at 17 March 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.